Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis

Journal of Endourology

Volumn 13, Issue 9, 1999, Pages 679-685

  Pearle, Margaret S ^a,b   Roehrborn, Claus G ^a   Pak, Charles Y C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CITRIC ACID; MAGNESIUM; PHOSPHATE; PLACEBO; THIAZIDE DIURETIC AGENT;

ARTICLE; CALCIUM OXALATE STONE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERCALCIURIA; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

EID: 0032801371     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.1999.13.679     Document Type: Article

References (48)

1. Marshall V, While RH, Chaput de Saintonage M, et al. The natural history of renal and ureteric calculi. Br J Urol 1975;47: 117-124.
2. Coe FL, Keck J, Norton ER. The natural history of calcium urolithiasis. JAMA 1977;238:1519-1523.
3. Blaylock NJ. The pattern of urolithiasis in the Royal Navy. In: Renal Stone Research Symposium. London: Churchill, 1968, pp 33-47.
4. Williams RC. Long-term survey of 538 patients with upper urinary tract stones. Br J Urol 1963;35:416.
5. Glowacki LS, Beecroft ML, Cook RJ, et al. The natural history of asymptomatic urolithiasis. J Urol 1992;147:319-321.
6. Clark JY, Thompson IM, Optenberg SA. Economic impact of urolithiasis in the United States. J Urol 1995;154:2020-2024.
7. Fine JK, Pak CYC, Preminger GM. Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. J Urol 1995;153:27-33.
8. Parks JH, Coe FL. The financial effects of kidney stone prevention. Kidney Int 1996;50:1706-1712.
9. Scholz K, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium nephrolithiasis. J Urol 1982;128:903-907.
10. Brocks P, Dahl C, Wolf H, et al. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 1981;2:124-125.
11. Ohkawa M, Tokunaga S, Nakashima T, et al. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol 1992;69:571-576.
12. Laerum S, Larsen S. Thiazide prophylaxis of urolithiasis: A double-blind study in general practice. Acta Med Scand 1984;215:383-389.
13. Ettinger B, Citron JT, Livermore B, et al. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988;139:679-684.
14. Robertson WG, Peacock M, Selby PL, et al. A multicentre trial to evaluate three treatments for recurrent idiopathic calcium stone disease: A preliminary report. In: Urolithiasis and Related Clinical Research. New York: Plenum Press, 1985, pp 545-548.
15. Wilson DR, Strauss AL, Manuel MA. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res 1984;12:39.
16. Miano L, Petta S, Galatioto GP, et al. A placebo controlled double-blind study of allopurinol in severe recurrent idiopathic renal lithiasis: Preliminary results. In: Urolithiasis and Related Clinical Research. New York: Plenum Press, 1985, pp 521-524.
17. Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-1389.
18. Barcelo P, Wuhl O, Servitge I, et al. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:1761-1764.
19. Hofbauer J, Höbarth K, Szabo N, et al. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis: A prospective randomized study. Br J Urol 1994;73:362-365.
20. Ettinger B, Pak CYC, Citron JT, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069-2073.
21. Ettinger B. Recurrent nephrolithiasis: Natural history and effect of phosphate therapy. Am J Med 1976;61:200-205.
22. Borghi L, Meshi T, Guerra A, et al. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993;22:S78-S86.
23. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
24. Scandinavian Simvastin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Sinvastin Survival Study (4S). Lancet 1994;344:1383-1389.
25. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronoary heart disease continuous and graded? Findings in 356,222 primary screens of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
26. Pekkanen J, Linn S, Heiss G, et al. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-1717.
27. Klag JM, Ford DE, Mead LA, et al. Serum cholesterol among young men ard subsequent cardiovascular disease. N Engl J Med 1993;328:313-318.
28. Newman WP III, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: The Bogalusa Heart Study. N Engl J Med 1986;314:
29. Ahlstrand C, Tiselius HG, Larsson L, et al. Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers. Br J Urol 1984;56:255-262.
30. Backman U, Danielson BG, Johansson G, et al. Effects of therapy with bendroflumethiazide in patients with recurrent renal calcium stones. Br J Urol 1979;51:175-180.
31. Sakhaee K, Harvey JA, Padalino PK, et al. Potential role of salt abuse on the risk for kidney stone formation. J Urol 1991; 150:310-312.
32. Silver J, Friedlaender MM, Rubinger D, et al. Sodium-dependent idiopathic hypercalciuria in renal stone-formers. Lancet 1983;2: 484-486.
33. Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982;22: 292-296.
34. Flocks RH. Calcium and phosphorus excretion in the urine of patients with renal or ureteral calculi. JAMA 1939;113:1466.
35. Pak CYC, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 1980;60:19-30.
36. Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 1977;87:404-410.
37. Elomaa I, Ala-Opas M, Porkka L. Five years of experience with selective therapy in recurrent calcium nephrolithiasis. J Urol 1984;132:656-661.
38. Pak CYC, Peters P, Hurt G, et al. Is selective therapy of recurrent nephrolithiasis possible? Am J Med 1981;71:615-622.
39. Yendt ER, Cohanim M. Absorptive hyperoxaluria: A new clinical entity successful treatment with hydrochlorothiazide. Clin Invest Med 1986;9:44-50.
40. Brickman AS, Massry SG, Coburn JW. Changes in serum and urinary calcium during treatment with hydrochorothiazide: Studies on mechanisms. J Clin Invest 1972;51:945-954.
41. Costanzo LS, Weiner IM. On the hypocalciuric action of chlorothiazide. J Clin Invest 1974;54:628-637.
42. Costanzo LS, Windhager E. Calcium and sodium transport by the distal convoluted tubule of the rat. Am J Physiol 1978;235: F492-F506.
43. Kunau RTJ, Weller DR, Webb HL. Clarification of the site of action of chlorothiazide in the rat nephron. J Clin Invest 1975;56:401-407.
44. Edwards BR, Baer PG, Sutton RAL, et al. Micropuncture study of diuretic effects on sodium and calcium reabsorption in the dog nephron. J Clin Invest 1973;52:2418-2427.
45. Yendt ER, Cohanim M. Prevention of calcium stones with thiazides. Kidney Int 1978;13:397-409.
46. Cohanim M, Yendt E. Reduction of urine oxalate during long-term thiazide therapy in patients with calcium urolithiasis. Invest Urol 1980;18:170-173.
47. Peña JC, Monforte MF, Briceño A. The role of oxalate and calcium oxalate activity and formation product ratio in patients with renal stones before and during treatment. J Urol 1987;138:1137-1140.
48. Pak CYC, Peterson R, Sakhaee K, et al. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med 1985;79:284-288.